 RUN-IN STAGE: Patients receive metformin hydrochloride orally PO twice daily BID and aspirin PO once daily QD for 4 months. Patients with disease progression PSA increase of 50 and minimum of 2ngml rise in PSA come off study. Patients achieving disease response 25 decline in PSA continue to receive study agents in the absence of disease progression or unacceptable disease. Patients with stable disease continue on to the randomized study regimen. 